Cancer Genetics and Epigenetics 2024, Vol.12, No.5, 234-253 http://medscipublisher.com/index.php/cge 251 Parikh A.R., Szabolcs A., Allen J.N., Clark J.W., Wo J.Y., Raabe M., Thel H., Hoyos D., Mehta A., Arshad S., Lieb D.J., Drapek L.C., Blaszkowsky L.S., Giantonio B.J., Weekes C.D., Zhu A.X., Goyal L., Nipp R.D., Dubois J.S., Van Seventer E.E., Foreman B.E., Matlack L.E., Ly L., Meurer J.A., Hacohen N., Ryan D.P., Yeap B.Y., Corcoran R.B., Greenbaum B.D., Ting D.T., and Hong T.S., 2021, Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial, Nature Cancer, 2(11): 1124-1135. https://doi.org/10.1038/s43018-021-00269-7 PMID: 35122060 PMCID: PMC8809884 Saxena M., van der Burg S.H., Melief C.J.M., and Bhardwaj N., 2021, Therapeutic cancer vaccines, Nature Reviews Cancer, 21(6): 360-378.https://doi.org/10.1038/s41568-021-00346-0 Schmitt M., and Greten F.R., 2021, The inflammatory pathogenesis of colorectal cancer, Nature Reviews Immunology, 21(10): 653-667. https://doi.org/10.1038/s41577-021-00534-x Schiller J.T., Lowy D.R., Frazer I.H., Finn O.J., Vilar E., Lyerly H.K., Gnjatic S., Zaidi N., Ott P.A., Balachandran V.P., Dietrich P.Y., Migliorini D., Vonderheide R.H., and Domchek S.M., 2022, Cancer vaccines, Cancer Cell, 40(6): 559-564. https://doi.org/10.1016/j.ccell.2022.05.015 Scolaro T., Manco M., Pecqueux M., Amorim R., Trotta R., Van Acker H.H., Van Haele M., Shirgaonkar N., Naulaerts S., Daniluk J., Prenen F., Varamo C., Ponti D., Doglioni G., Campos A.M.F., Garcia J.F., Radenkovic S., Rouhi P., Beatovic A., Wang L.W., Wang Y., Tzoumpa A., Antoranz A., Sargsian A., Di Matteo M., Berardi E., Goveia J., Ghesquière B., Roskams T., Soenen S., Voets T., Manshian B., Fendt S.M., Carmeliet P., Garg A.D., DasGupta R., Topal B., and Mazzone M., 2024, Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance, Nature Cancer, 6: 1-21. https://doi.org/10.1038/s43018-024-00771-8 PMID: 38844817 PMCID: PMC11358017 Shan F., Somasundaram A., Bruno T.C., Workman C.J., and Vignali D.A.A., 2022, Therapeutic targeting of regulatory T cells in cancer, Trends in Cancer, 8(11): 944-961. https://doi.org/10.1016/j.trecan.2022.06.008 Shi G., Yang Q.M., Zhang Y.J., Jiang Q.Y., Lin Y., Yang S.S., Wang H.L., Cheng L., Zhang X., Li Y.M., Wang Q.N., Liu Y., Qin Wang Q., Hantao Zhang H.T., Su X.L., Dai L., Liu L., Zhang S., Li J., Li Z., Yang Y., Yu D.C., Wei Y.Q., and Deng H.X., 2019, Modulating the tumor microenvironment via oncolytic viruses and CSF-1R inhibition synergistically enhances Anti-PD-1 immunotherapy, Molecular Therapy, 27(1): 244-260. https://doi.org/10.1016/j.ymthe.2018.11.010 Shibata T., 2022, Diverse molecular mechanisms for immune evasion in gastrointestinal cancer, Gan to kagaku ryoho Cancer & Chemotherapy, 49(3): 243-247. Singh M., Morris V.K., Bandey I.N., Hong D.S., and Kopetz S., 2024, Advancements in combining targeted therapy and immunotherapy for colorectal cancer, Trends in Cancer, 10(7): 598-609. https://doi.org/10.1016/j.trecan.2024.05.001 Song J.J., Zhang Y.J., Zhou C.L., Zhan J.H., Cheng X.F., Huang H.Y., Mao S.X., and Zong Z., 2024, The dawn of a new Era: mRNA vaccines in colorectal cancer immunotherapy, International Immunopharmacology, 132: 112037. Subtil B., Cambi A., Tauriello D.V.F., and de Vries I.J.M., 2021, The therapeutic potential of tackling tumor-induced dendritic cell dysfunction in colorectal cancer, Frontiers in Immunology 12: 724883. https://doi.org/10.3389/fimmu.2021.724883 Sun R., Limkin E.J., Vakalopoulou M., Dercle L., Champiat S., Han S.R., Verlingue L., Brandao D., Lancia A., Ammari S., Hollebecque A., Scoazec J.Y., Marabelle A., Massard C., Soria J.C., Robert C., Paragios N., Prof Eric Deutsch E., and Ferté C., 2018, A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study, The Lancet Oncology, 19(9): 1180-1191. https://doi.org/10.1016/S1470-2045(18)30413-3 Taghiloo S., and Asgarian-Omran H., 2021, Immune evasion mechanisms in acute myeloid leukemia: a focus on immune checkpoint pathways, Critical Reviews in Oncology/Hematology, 157: 103164. https://doi.org/10.1016/j.critrevonc.2020.103164 Tang S., Ning Q., Yang L., Mo Z.C., and Tang S.S., 2020, Mechanisms of immune escape in the cancer immune cycle, International Immunopharmacology, 86: 106700. https://doi.org/10.1016/j.intimp.2020.106700 Tang T.Y., Huang X., Zhang G., Hong Z.T., Bai X.L., and Liang T.B., 2021, Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy, Signal Transduction and Targeted Therapy, 6(1): 72. https://doi.org/10.1038/s41392-020-00449-4 Taniura T., Iida Y., Kotani H., Ishitobi K., Tajima Y., and Harada M., 2020, Immunogenic chemotherapy in two mouse colon cancer models, Cancer Science, 111(10): 3527-3539. https://doi.org/10.1111/cas.14624 Tian J., Chen J.H., Chao S.X., Pelka K., Giannakis M., Hess J., Burke K., Jorgji V., Sindurakar P., Braverman J., Mehta A., Oka T., Huang M., Lieb D., Spurrell M., Allen J.N., Abrams T.A., Clark J.W., Enzinger A.C., Enzinger P.C., Klempner S.J., McCleary N.J., Meyerhardt J.A., Ryan D.P., Matthew B. Yurgelun, Katie Kanter K., Van Seventer E.E., Baiev I., Chi G., Jarnagin J., Bradford W.B., Wong E., Michel A.G., Fetter I.J., Siravegna G., Gemma A.J., Sharpe A., Demehri S., Leary R., Campbell C.D., Yilmaz O., Getz G.A., Parikh A.R., Hacohen N., and Corcoran R.B., 2023, Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial, Nature Medicine, 29(2): 458-466.
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==